Quick Facts: Therapeutic Domain

• Active Duodenal Ulcer: Treatment for active ulcerations in the first part of the small intestine.
• Duodenal Ulcer Maintenance: Used after healing to help prevent recurrence.
• Gastric Ulcer & Gastritis: May be used in the management of stomach ulcers and inflammation.

---

Gastrofait is prescribed for the management of specific conditions affecting the upper gastrointestinal tract. Its primary approved application is the short-term treatment of active duodenal ulcers. Following the initial healing phase of the active ulcer, the medication may also be used as a maintenance treatment to help prevent the ulcer from recurring.

Beyond its core use, the drug may be utilized to address other related gastrointestinal concerns, including gastric ulcers (ulcers in the stomach) and gastritis (stomach lining inflammation). It functions by creating a localized protective layer that adheres to the ulcer site. This layer acts as a mechanical barrier, which protects the affected mucosa from damaging stomach contents, such as acid and digestive enzymes, thereby supporting the natural healing process.

For comprehensive information regarding the drug's approved uses and safety profile, patients should consult authoritative drug information.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Gastrofait?

The population eligibility for Gastrofait (Sucralfate) is strictly governed by regulatory classifications, detailing who may use the medicine and under what conditions.

Contraindications and Restrictions

Category	Official Regulatory Status
Absolute Prohibition	The medicine is contraindicated for patients with a known hypersensitivity to sucralfate or any of its excipients.
Renal Impairment	Use is limited and requires caution in patients with chronic renal failure or impaired renal function, as the aluminum component risks accumulation and toxicity in these individuals.
Pediatric Patients	Safety and effectiveness have not been established in the pediatric population (under 18 years old).

---

Special Population Considerations

Category	Official Regulatory Status
Pregnancy	Use is categorized as Category B by the US FDA. It should be used only if clearly needed, due to insufficient data from controlled studies in pregnant women.
Older Adults	Caution is advised in dose selection, primarily due to the greater frequency of decreased renal function in this group, which impacts aluminum excretion.
Bezoar Risk	Caution is advised for patients with underlying conditions, such as delayed gastric emptying, that may predispose them to the formation of a bezoar (solid mass).

---

Official regulatory documents define eligibility by strictly prohibiting use in cases of known allergy and by imposing restrictions based on patient physiology, specifically focusing on the risk of aluminum accumulation in those with impaired renal function. Use is not established in children and requires caution in the elderly.

Interactions with Other Medicines and Products

Gastrofait (Sucralfate) has an official interaction profile defined by its local, nonsystemic action in the digestive tract, which primarily results in pharmacokinetic interactions related to drug absorption.

Absorption-Based Interactions and Timing Rules

Co-administration may reduce the systemic exposure (bioavailability) of multiple orally administered medications. This absorption reduction affects classes including H2 antagonists (e.g., Cimetidine, Ranitidine), Fluoroquinolone antibiotics, Digoxin, Phenytoin, and L-thyroxine.

To prevent this documented reduction in exposure, regulatory documents specify a mandatory timing separation: these affected medications must be administered 2 hours prior to Gastrofait. Other drugs for which altered bioavailability is a concern should also be administered separately.

Pharmacodynamic and Population Cautions

The medication's aluminum component creates a pharmacodynamic risk when used with other aluminum-containing products, such as antacids, as this combination may increase the total body burden of aluminum. Antacids must be separated by one-half hour from Gastrofait administration. Co-administration with citrate preparations is formally not recommended.

A specific population-dependent interaction caution exists for patients with chronic renal failure or those on dialysis. Their impaired ability to excrete aluminum leads to a heightened risk of aluminum accumulation and related toxicity, as documented in the official prescribing information.

The mechanism of Gastrofait (Sucralfate) involves highly localized, non-systemic cytoprotection achieved through physical isolation and the enhancement of biochemical repair pathways.

---

Physical Barrier Formation and Protection

Sucralfate undergoes polymerization in the acidic gastric environment ( pH le 4), transforming into a viscous, negatively charged gel that selectively binds to the positively charged proteins exposed at the site of tissue damage. This electrostatic binding creates a durable, protective physical barrier over the lesion. This action impedes the contact between underlying tissue and gastric fluid components, including the back-diffusion of hydrogen ions ( H^+).

---

Inactivation of Luminal Aggressors

The polymeric barrier also acts as a localized chemical mitigation component. It physically adsorbs and non-competitively inhibits the proteolytic enzyme Pepsin A and binds to toxic Bile Salts present in the digestive tract. This chemical inactivation reduces the activity of proteolytic enzymes and binding to bile salts; this action complements the physical shield and limits further chemical degradation of the injured site.

---

Enhancement of Endogenous Healing

Beyond the protective shield, the mechanism facilitates natural repair processes. The physical barrier preserves local Growth Factors ( FGF-2, Pro-EGF) from acid degradation, concentrating them to promote cell proliferation and re-epithelialization. Additionally, the mechanism stimulates local Prostaglandin synthesis, which enhances the body's intrinsic defenses by increasing mucosal blood flow and the secretion of protective mucus and bicarbonate.

Gastrofait, which contains the active ingredient sucralfate, is prescribed for oral use, typically to treat active duodenal ulcers for up to eight weeks. It functions primarily through a local action in the gastrointestinal tract, where it forms a protective barrier over the ulcer site against gastric acid, pepsin, and bile salts, promoting a healing environment.

Dosage and Administration

For the treatment of an active duodenal ulcer, the standard adult oral dosage is 1 gram four times daily. It is crucial to administer this medication on an empty stomach for optimal effect. A common regimen involves taking the dose one hour before each meal and another at bedtime.

Administration Detail	Recommendation
Timing	On an empty stomach (e.g., 1 hour before meals and at bedtime)
Antacids	Should not be taken within 30 minutes before or after Gastrofait
Missed Dose	Take the missed dose as soon as possible, unless it is almost time for the next scheduled dose. Do not double the dose

Important Considerations

Sucralfate is minimally absorbed; however, it contains aluminum. Patients with chronic renal failure or those on dialysis should use Gastrofait with caution, as they have an impaired ability to excrete absorbed aluminum, which can lead to accumulation and potential toxicity. Concomitant use with other aluminum-containing products, such as certain antacids, may increase this risk. Additionally, certain medications should be taken two hours prior to Gastrofait to prevent potential drug interactions that could alter absorption.

Research Evidence / Overview of Studies for Gastrofait

This section summarizes the official research evidence for Sucralfate (the active ingredient in Gastrofait), focusing only on the types of studies conducted and the overall patterns described by researchers, without offering medical advice or treatment recommendations.

---

Evidence for Use in Treating Active Duodenal Ulcers

Initial clinical evaluation involved short-term, randomized controlled trials (RCTs). Research evaluated Sucralfate in adult patients who had endoscopically confirmed active ulcers in the duodenum. These studies examined patient-reported outcomes related to physical discomfort and monitored the ulcer status over treatment periods typically ranging from four to eight weeks.

Findings from these controlled trials, which included comparisons to inactive substances (placebo) and other older anti-ulcer medications, described patterns observed in the rates of endpoint status evaluation. What remains uncertain is how well these findings apply in the context of current standards of care, as the majority of this foundational research was conducted before the routine protocol of clearing the H. pylori bacteria was fully established.

Evidence for Preventing Duodenal Ulcer Recurrence (Maintenance)

Following the healing of an active duodenal ulcer, research examined Sucralfate in a maintenance setting to explore patterns related to the return of ulcers. These studies focused on longer-term, randomized controlled trials comparing the drug to placebo over observation periods that lasted up to one year. Researchers monitored outcomes describing episodic or acute changes by tracking the rate of relapse, confirmed by repeated examinations.

The research framework exploring prevention of recurrence also shares a similar limitation with the acute treatment trials: the data show patterns related to observation in a research context that pre-dates modern approaches to H. pylori management. Comparative evidence against current first-line maintenance therapies is lacking.

Research Gaps and Areas of Uncertainty

The main body of evidence supporting the drug's clinical evaluation comes from studies that focused on the general adult population with peptic ulcers. Data for certain groups, such as older adult populations or patients with complex concurrent diseases, remain insufficient. Research exploring Sucralfate was primarily focused on duodenal and gastric ulcers, and data for other conditions, such as non-ulcer dyspepsia, is less extensive.

Key Studies & References Sucralfate: NIH MedlinePlus Guidance (Professional Monograph for approved uses and study context)

Common questions about Gastrofait (FAQ)

Q: How quickly should I expect Gastrofait to start working?

Gastrofait is a local-acting medication designed to form a protective barrier over the ulcer site quickly in the acidic environment of the stomach. While the physical barrier forms rapidly, symptomatic relief for patients may be noticed within the first one to two weeks of treatment. The full duration of the prescribed treatment is typically required to promote complete ulcer healing.

---

Q: Can taking Gastrofait make you feel tired or dizzy?

According to official product information, dizziness, vertigo, and sleepiness (somnolence) have been reported, but they are generally uncommon adverse reactions, occurring in less than 0.5% of patients. Unusual tiredness or weakness is not typically listed as a common or uncommon side effect of this medication.

---

Q: Is it normal to have mild constipation when using Gastrofait?

Constipation is the most frequently reported side effect of Gastrofait in clinical trials. Official data indicates it occurs in 1% to 10% of patients. Patients experiencing persistent or severe constipation are advised to consult a healthcare professional.

---

Q: Are there any foods or drinks I should avoid while on Gastrofait?

Official guidance emphasizes taking Gastrofait on an empty stomach to ensure it works properly, typically one hour before meals. Patients must also separate their dose from antacids and other specific medicines. However, there are no specific foods or drinks (such as coffee, tea, or acidic foods) that are explicitly prohibited in the regulatory prescribing information.

---

Q: How is Gastrofait different from omeprazole or ranitidine?

Gastrofait is fundamentally different from acid-reducing medicines like omeprazole (a proton pump inhibitor) or ranitidine ( H2 antagonist). Gastrofait is a cytoprotective agent that works locally to form a physical barrier over the ulcer site. Omeprazole and ranitidine work systemically to reduce the amount of acid the stomach produces.

---

Q: Is Gastrofait safe to use for a long period, or is it only for short-term use?

The official indication for Gastrofait is the short-term treatment of active duodenal ulcers, typically for a period of up to eight weeks. It is also approved for maintenance therapy for up to one year to help prevent ulcers from returning. Long-term use beyond these established periods is not fully covered in the official prescribing information.

---

Q: Can children take Gastrofait for stomach issues?

According to the official prescribing information, the safety and effectiveness of Gastrofait have not been established in pediatric patients (children under 18 years old).

---

Q: Is Gastrofait considered safe during pregnancy or breastfeeding?

The medication is categorized as Pregnancy Category B, and official guidance indicates its use during pregnancy is reserved for when the potential benefit is judged to outweigh the potential risk. It is not currently known whether the drug is excreted in human milk, and consultation with a healthcare professional is generally recommended before use during breastfeeding.

---

Q: Do I need a prescription for Gastrofait, or can I buy it over the counter?

Gastrofait (Sucralfate) is a prescription-only medication, meaning it must be obtained with a prescription from a licensed healthcare provider.

---

Q: Does Gastrofait have any known interactions with blood thinners?

There have been reports of reduced effect when Gastrofait is taken with warfarin, a common blood thinner. Although some studies showed no change, the official documentation suggests the potential for interaction exists. Official documentation advises appropriate monitoring if these two drugs are used together.

---

Q: Is Gastrofait effective for all types of ulcers, or just certain ones?

Gastrofait is officially indicated for the short-term treatment of active duodenal ulcers (ulcers in the upper part of the small intestine). Limited clinical studies have suggested benefit for gastric ulcers, but this is not an official FDA-approved indication.

---

Q: Can Gastrofait affect the results of lab tests?

The oral suspension formulation contains carbohydrates, and there have been reports of high blood sugar (hyperglycemia) in diabetic patients, which may impact blood glucose monitoring. Additionally, the drug has phosphate-binding properties. In diabetic patients using the suspension, consultation with a healthcare professional is recommended regarding blood glucose monitoring.

---

Q: Do older adults (seniors) need to worry about specific side effects from Gastrofait?

Official guidance recommends caution in dose selection for older adults, primarily because reduced kidney function is more frequent in this population. This impairment increases the risk of aluminum accumulation and toxicity over time, as the drug contains aluminum.

---

Q: Is there a generic version of Gastrofait available?

Yes, generic versions of the active ingredient, sucralfate, are approved and available in both tablet and oral suspension forms.

---

Q: Does Gastrofait cause weight gain or loss?

Weight gain or weight loss are not listed among the common or uncommon reported adverse reactions in the official prescribing information for Gastrofait.

---

Q: How long after taking Gastrofait can I drink coffee or tea?

Since the medication is intended to be taken on an empty stomach to allow optimal coating, it is generally recommended to wait at least one hour after taking a dose before consuming food or beverages like coffee or tea.

---

Q: Are there different forms of Gastrofait, like tablets vs. liquid suspension?

Yes, Gastrofait is typically provided for oral administration in both a solid tablet form and an oral suspension (liquid) form.

---

Q: Can Gastrofait be crushed or mixed with food if swallowing is difficult?

While the official tablet is generally swallowed whole, some tablet formulations are designed to be dispersed in a small amount of water for easier swallowing. The oral suspension is also available for patients who have difficulty taking tablets.

---

Q: Are there any herbal supplements that interact with Gastrofait?

The official product information advises telling a healthcare provider about all current medicines, including herbal products and vitamins. This is because Gastrofait can affect the absorption of many different orally administered agents, necessitating a time separation.

---

Q: Why do some people take Gastrofait for problems not related to ulcers?

While the medication is officially indicated for duodenal ulcers, the mechanism of forming a protective coating means it is sometimes cited in medical literature for 'off-label' uses. These may include conditions requiring mucosal protection, such as treating inflammation in the esophagus (esophagitis) or mouth (stomatitis).

---

Q: Is Gastrofait a medication that heals or just one that protects?

Gastrofait does both: it works primarily by forming a physical shield to protect the ulcer site from damage by stomach acid and pepsin. This protective action, in turn, promotes the natural healing of active duodenal ulcers.

---

Q: Does Gastrofait contain sugar, and is it safe for diabetics?

The oral suspension formulation contains carbohydrates. Because of this, cases of high blood sugar (hyperglycemia) have been reported in diabetic patients using the liquid form. In diabetic patients using the suspension, consultation with a healthcare professional is recommended regarding blood glucose monitoring.

---

Q: Can taking Gastrofait lead to low phosphate levels?

Yes, due to its aluminum component, Gastrofait has phosphate-binding properties, and low phosphate levels (hypophosphatemia) may occur. Consultation with a healthcare provider is recommended for individuals with pre-existing low phosphate levels before using this medication.

---

Q: Is Gastrofait an antibiotic, or does it fight bacteria like H. pylori?

Gastrofait is a cytoprotective agent, not an antibiotic. While it is not intended to treat H. pylori infection, some studies suggest it may potentially enhance the effect of antibiotics when they are used together to clear the bacteria.

---

Q: Do doctors ever use Gastrofait for throat or esophageal issues?

The official indication is for duodenal ulcers. However, the suspension form is often cited in medical literature for off-label uses related to symptoms of gastroesophageal reflux disease (GERD) in the esophagus or for coating ulcers in the mouth and throat.

---

Q: What if I experience a rash or itching after starting Gastrofait?

Rash and itching are reported adverse reactions. The regulatory documents advise seeking immediate emergency assistance if a patient experiences signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, as serious hypersensitivity events have been reported.

---

Q: Is it better to take Gastrofait before or after a meal?

Official guidance is very clear that Gastrofait should be taken on an empty stomach for optimal efficacy. This means it should be taken one hour before each meal and at bedtime, rather than immediately after a meal.

How to Store and Dispose of Gastrofait?

The storage and disposal instructions for Gastrofait (sucralfate) are strictly governed by regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, specifically 20 --25 C (68 --77 F).
Handling	The oral suspension form must be protected from freezing.
Container	Keep in the original container and ensure it is tightly closed to protect it from moisture and excess heat.
Child Safety	The medication must be kept out of the sight and reach of children.

Disposal

Unused or expired Gastrofait must be disposed of according to local and national environmental regulations. Official guidance advises against flushing the product down the toilet or pouring it into any wastewater system unless explicitly instructed to do so by a healthcare professional.